Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

400
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
400
Depression: Overview01:18

Depression: Overview

405
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
405
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

232
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
232
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

694
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
694
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

231
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
231
Long-term Depression01:05

Long-term Depression

31.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
31.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) 2025 international guidelines for the management of patients with obsessive-compulsive disorder.

Journal of psychiatric research·2026
Same author

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Psychopharmacology·2026
Same author

Prediction modeling in transdiagnostic risk: results from the PROCAN study.

Brain imaging and behavior·2026
Same author

Neuroimaging insights on sleep disturbances and risk for major depressive disorder in youth: A systematic review.

Comprehensive psychiatry·2026
Same author

High‑Resolution Clinical Profiling of Age and Sex Differences in Substance Use Severity, Comorbidity, and Impulsivity in Two Large Treatment Samples.

Substance use & misuse·2026
Same author

Corrigendum to "Revisiting subcallosal cingulate deep brain stimulation for depression: Long-term safety and effectiveness outcomes from a pooled analysis of 172 implanted patients" [Brain Stimul 18 (2025) 1632-1640].

Brain stimulation·2026

Related Experiment Video

Updated: Oct 1, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

221

Beyond Response: Aiming for Quality Remission in Depression.

Sidney H Kennedy1

  • 1Centre for Depression and Suicide Studies, St Michael's Hospital, University of Toronto, 193 Yonge Street, Suite 6-001A, Toronto, ON, M5B 1M4, Canada. sidney.kennedy@uhn.ca.

Advances in Therapy
|March 5, 2022
PubMed
Summary

Many depression patients don't fully recover, even with a 50% symptom reduction. Achieving functional recovery alongside symptom relief is crucial for overall treatment success in depression.

Keywords:
AdherenceAntidepressantsDepressionFunctioningPersistenceResidual symptomsResponseTreatment

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

840
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.7K

Related Experiment Videos

Last Updated: Oct 1, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

221
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

840
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.7K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Defining treatment response in depression solely by symptom reduction leaves many patients with residual symptoms affecting daily functioning.
  • Patient-centered goals for depression treatment emphasize returning to premorbid levels of functioning, not just symptom alleviation.

Purpose of the Study:

  • To evaluate the importance of assessing both symptomatic and functional outcomes in depression treatment.
  • To compare the efficacy of agomelatine and escitalopram in achieving both symptomatic and functional response.

Main Methods:

  • Analysis of data from two studies, one involving agomelatine and another involving escitalopram.
  • Assessment of symptomatic response (≥50% symptom reduction) and functional response in patients with depression.

Main Results:

  • While both agomelatine and escitalopram showed symptomatic and functional response rates, a significant proportion of patients achieved only one or neither.
  • Agomelatine achieved a dual symptomatic and functional response in 42% of patients, compared to 35% for escitalopram.
  • Fatigue and impaired concentration were identified as key symptoms significantly impacting occupational functioning.

Conclusions:

  • Symptomatic response alone is insufficient; functional recovery is a critical measure of successful depression treatment.
  • Ongoing assessment of functional impairment, particularly symptoms like fatigue, is essential for managing depression.
  • Treatment selection should consider efficacy, side effects, and patient adherence to maximize long-term outcomes.